Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Care: Riluzole in ALS
NCT00542412Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of riluzole in amyotrophic lateral sclerosis (ALS), sponsored by Sanofi. Primary endpoint: Time to the occurrence of an ALS-related event (PAV, tracheostomy or ALS-related death). Started Jan 2001; status: completed.
02
Drugs
riluzole
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT00542412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542412.